Greetings. Welcome to Aytu BioPharma Fiscal 2023 Q2 Results Conference Call. At this time, all participants are in listen-only mode. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. Question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Roger Weiss. You may begin. Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's second quarter fiscal year 2023 financial results conference call. Joining us today on the call is Aytu's CEO, Josh Disbrow, and the company's Chief Financial Officer, Mark Oki. At the conclusion of today's prepared remarks, we'll open the call for a question and answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the earnings press release issued earlier today. I'd also like to call your attention to the customary safe harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential operating results of Aytu BioPharma. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties, and other factors, including but not limited to, the factors set forth in the company's filings with the SEC. Aytu undertakes no obligation to update or revise any of these forward-looking statements. With that said, I'd like to turn the event over to Josh Disbrow, Chief Executive Officer of Aytu BioPharma. Josh, please proceed. Thank you, Roger, and welcome everyone. First off, I'd like to share how extremely pleased I am with the recent momentum the business has gained as we report our second consecutive quarter of company-wide positive Adjusted EBITDA and strong revenue growth. Achieving positive Adjusted EBITDA for the second consecutive quarter is another key milestone for Aytu and helps to positively change the trajectory of Aytu in the years to come. I'm very enthusiastic about our continuing momentum into this current March quarter, particularly in prescription trends as the ADHD franchise posted all-time weekly RX numbers here in February. More on that as we get into specifics. As outlined in today's press release, quarterly net revenue increased by 14% compared to the year ago quarter to $26.3 million, driven by strong performance in our RX segment. The RX segment experienced 23% revenue growth to $18 million due to the continuing execution of our sales force and the leverage we're generating through Aytu RxConnect, our novel and proprietary patient access program, along with some market tailwinds associated with the ADHD stimulant shortages, which we are capitalizing on. Within the RX segment, pediatric portfolio net revenue increased 95%, while ADHD scripts for the quarter rose 8.1% sequentially, highlighting the growing demand for our products. Our RX segment had a positive Adjusted EBITDA of $3.1 million, an improvement compared to the negative Adjusted EBITDA reported in the year-ago period of $1.9 million and was also a sequential increase from our first fiscal quarter of 2023. This is now the third consecutive quarter in which the prescription segment has had positive Adjusted EBITDA. I'll explain more on that business in a bit. On the consumer health side, the segment continues to execute on our objective to improve segment profitability with a focus on more efficient, higher contribution margin online sales channels, resulting in a significant 30% improvement in the segment's negative Adjusted EBITDA. As we discussed a bit last quarter, near-term revenue from the consumer health segment will likely be impacted as we phase out the direct mail channel and focus on the more profitable OTC medicines and their e-commerce sales channel. As we prepare to launch our Circle Health branding initiative later this year, we believe we are well positioned to build upon our recent gains and propel this segment forward to generating positive Adjusted EBITDA and thereafter to free cash flow. I'll expand more on this in a moment as well. All told, Adjusted EBITDA for the company was a positive $0.7 million during the second quarter of 2023, which compares to a negative $7.6 million in last year's second quarter, an improvement of more than $8 million. I would also like to note that the company generated a positive $2 million of Adjusted EBITDA when you exclude the residual expenditures associated with the now suspended clinical development programs. This pro forma Adjusted EBITDA highlights the operating strength that Aytu has going forward. On October 13th of last year, we announced an important shift of the company's strategy aimed at accelerating the growth of our commercial business and achieving profitability. We suspended our clinical development programs, including AR101 or enzastaurin, for the treatment of vascular Ehlers-Danlos syndrome. The suspension is expected to save the company over $20 million in projected future study costs, allowing us to continue the upward trajectory of our positive Adjusted EBITDA. We have refocused our efforts on growing revenue, maximizing synergies, and driving down expenses, all of which will serve to accelerate our path to profitability. With our second Adjusted EBITDA quarter now in hand, that path has become markedly clearer. Let's dive into the commercial business a bit more, beginning with our Rx segment. As a reminder, within the Rx segment, we operate primarily in two therapeutic areas, ADHD and pediatrics. Let's start with ADHD. This portfolio includes Adzenys XR-ODT and Cotempla XR-ODT, the first and only FDA-approved amphetamine and methylphenidate extended-release orally disintegrating tablets, respectively, for the treatment of ADHD. These extended-release stimulant medications are formulated in patient-friendly oral disintegrating tablets that utilize our proprietary microparticle modified-release drug delivery technology platform. During the quarter, our ADHD products contributed $11.1 million in net revenue, an increase of 2% compared to a year-ago period and down 4% sequentially. There's a little bit of noise in the revenue number, however, as the scripts were actually up over 8% sequentially. We believe the script number is a better characterization of prescriber and patient demand and the revenue impact during the quarter is largely due to the end-of-year shipping issues resulting from sustained inclement weather throughout the holidays. Remember that there was a significant winter storm that impacted logistics in the U.S. at the end of calendar 2022, That delayed some of our shipments. We expect to see the timing of this issue catch up to itself in the current quarter. The market dynamics surrounding ADHD continue to provide tailwinds for the company. First, we continue to see overall growth in the ADHD market as we see an increase in diagnoses. According to the health data company Trilliant Health, Adderall prescriptions for adults rose 15.1% during 2020, double the 7.4% rise seen the year before. The impacts from the various generic Adderall XR manufacturer delays and supply disruptions I talked about last quarter still remain. Just last week, a Bloomberg article reported once again discussing the ongoing impact of these shortages. Our supply has remained robust and uninterrupted. We believe the competitive supply disruptions over the past few quarters have enabled Adzenys to gain market share and mind share, and in fact, we're seeing evidence of that in the data. As a reminder, Adzenys is approved as bioequivalent to Adderall XR, our brand is well-positioned to continue to capture additional share as the remnants of the extended-release amphetamine shortage remain. To further highlight how we're continuing to leverage the ongoing Adderall XR shortage and our execution, I'll note that for the week ending February 10th, Adzenys registered over 7,200 total prescriptions. This is an all-time high and is up 26% from the previous week. This is by far the highest weekly TRx level ever registered for the brand. Cotempla also registered among its highest weekly numbers with over 3,200 TRxs that same week. This is up 16% over the previous week. We're now hearing of methylphenidate shortages and know of Johnson & Johnson's discontinuation of the Concerta authorized generic. Now both of our ADHD brands have significant market factors providing tailwinds that we believe may persist for some time. For the four weeks ending February 10th, our combined ADHD scripts are up 20% over the preceding four weeks, and again, at an all-time high level. Across the entire Rx portfolio, we're up 24% year-to-date over last year. To say the very least, we have tremendous momentum on our side with our prescription brands. Beyond the macro tailwinds, I believe our team has done a tremendous job creating and delivering on the tools headlined by RxConnect and building a highly motivated and refreshed sales team to drive growth. I'll remind you that following the acquisition of Neos nearly two years ago, we began the process of revamping the sales force. With a preference for newer-to-industry sales representatives and a stronger pay-for-outsized performance compensation model, we turned over a large portion of the former Neos sales team. This transition and change of mindset took time, but it has now begun paying dividends across this still new and highly motivated sales team. In conjunction with our commercial team, a key part of our success lies with Aytu RxConnect. With RxConnect, we have roughly 1,000 network pharmacies in key markets across the country on the platform. RxConnect creates real value for all stakeholders, so we seek to drive our prescriptions through that platform. Compared to prescriptions filled outside the platform, Aytu RxConnect results in nearly 50% reduction in patient out-of-pocket co-payments, a 2x improvement in Aytu's net margin per Rx, and a more than 40% increase in prescription refills by patients. The platform truly does drive value for patients, healthcare providers, and Aytu, which of course has been the purpose since the inception of the program. With Aytu RxConnect, the growth of this platform can largely be attributed to the fact that many prescriber hassles associated with dealing with payers are removed. Further, patients' co-pays remain consistent and predictable, and the friction patients and clinicians often experience when writing and filling branded scripts largely goes away. Going forward, RxConnect will continue to leverage our current products and the new products we are evaluating to bring into the portfolio. Again, we're pleased with where we are, but I am most excited about where we're going with these great recent script trends. A lot of work has gone into creating this momentum, and I'm grateful to the entire team for putting us in such a strong position. Before I transition to the pediatric portfolio, just a quick note on the manufacturing transfer of both Adzenys and Cotempla that we have underway, which is expected to further improve our profitability. As we reported back in September, the process is well underway with the prospective contract manufacturer including the conduct of bioequivalent studies and the other required work. It is our goal of having everything finalized and the CMO producing our ADHD products in calendar 2023. This outsourcing stands to improve the gross profit margin of the ADHD brands by 15% or more, a meaningful step change that, if achieved, will further improve our P&L. More to follow as this process continues. We are pleased with our progress on this front. Let's now transition to our pediatric portfolio, which includes Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based multivitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. We also market Karbinal ER, an extended-release carbinoxamine-based antihistamine suspension indicated to treat numerous allergic conditions for patients two years and older. These products serve large, established pediatric markets and offer distinct clinical features and patient benefits over both branded and generic competitive products. During the quarter, we achieved 95% growth in revenue from our prescription pediatric line, with revenue ramping to $6.3 million. This was in addition to the 73% year-over-year growth in revenue from pediatric products that we achieved in the first quarter. The growth just continues. Similar to our ADHD portfolio, the key drivers here are the improved sales force execution as well as the Aytu RxConnect platform leverage. These improvements are providing tailwinds for the product's prescription growth trajectory. Since we added PVF and TVF to the RxConnect platform, we have grown prescriptions significantly and continue to demonstrate remarkable growth. The most recent CDC data shows that only 63% of the U.S. population has access to fluoridated water, and in some states like New Jersey, that percentage is in the mid-teens or even less. We're continually evaluating geographic expansion opportunities for the fluoride multivitamin line as we look to additional areas in need of fluoride supplementation. We believe that growth across both new and existing geographies will serve as the basis from which we will continue to grow Poly-Vi-Flor and Tri-Vi-Flor sales. To provide additional recent context on the growth of our pediatric brands, I'll note the tremendous growth they're also experiencing. Again, using the week ending February 10th, when we look at the year-to-date prescription growth over the same period last year, combined Poly-Vi-Flor and Tri-Vi-Flor scripts are up over 120%, while Karbinal scripts are up over 33%. Overall, I'm pleased with the traction we're achieving across our Rx segment. As mentioned, we experienced 23% revenue growth in the second quarter and generated a positive $3.1 million in Adjusted EBITDA, our third consecutive quarter with positive Rx segment Adjusted EBITDA. With continued growth, cost reductions, and gross margin improvement measures in place, we expect to continue the positive EBITDA quarters going forward. Let's transition to our consumer health segment now. As a reminder, within consumer health, our core product focus is on branded, value-based products competing in large categories such as hair loss, digestive health, diabetes management, and allergy, all competing with large national brands. We sell directly to consumers through e-commerce platforms, including branded websites and on the Amazon platform. Additionally, the consumer segment sells products through our proprietary sales and marketing platform, which focuses primarily on direct mail. As we touched on last quarter, our objective has been to improve consumer health segment profitability with a focus on more efficient, higher contribution margin online sales channels. As a result, we are phasing out the direct mail channel in order to focus on higher profitability OTC medicines and specifically through our e-commerce channel. This shift may negatively impact revenues in the near term, but will drive improved EBITDA within the consumer health segment. Focusing our efforts on the more profitable OTC e-commerce portfolio, which I'll point out grew 70% over the year-ago quarter, resulted in Adjusted EBITDA for the segment improving by 30% or nearly $500,000. This improvement was achieved despite the segment experiencing a 3% year-over-year decrease in total segment revenue to $8.3 million. Our efforts to drive sustainable, profitable growth in this segment are beginning to pay off. As we have alluded to in the past, and a big part of consumer health's growth plan, we are establishing a value brand called Circle Health, which we expect to officially launch later this year. Circle Health will represent a brand family of value-based, over-the-counter medicines addressing a range of conditions. Showcasing our OTC medicine products through a single recognized family brand will build more collective brand equity. This brand initiative is expected to create a common one-stop shop for families seeking value brands addressing common, everyday conditions, ultimately driving more repeat customer sales, thus yielding higher overall margins and creating annuity value. As part of the formation of the Circle brand, we expect to rebrand existing products, add new products, and integrate all those into the Circle brand family. More to follow as we approach the Circle launch. Before I turn it over to Mark, let me just say how incredibly proud I am of the entire organization. The team continues to rally around the opportunity to build a truly great execution-oriented company, which has led to strong revenue growth and our second consecutive quarter with positive company-wide Adjusted EBITDA. Again, the prescription trends through the middle of February are very encouraging to further add to our strong position. With initiatives in place for further growth, coupled with operational improvements and further cost reductions and margin improvements during the remainder of the fiscal year, we are in a much stronger financial position to drive long-term shareholder value. With that overview now complete, let me turn it over to our CFO, Mark Oki, with some additional color to the numbers. Mark? Thank you, Josh, and welcome to everyone joining us on the call. Earlier today, you may have seen that we filed a Form 10-Q/A to restate our first quarter earnings. During the second quarter, we evaluated the accounting for previously granted warrants included in debt and equity transactions. With this, the company concluded that certain warrants should have been accounted for as a liability rather than as equity. The changes resulted in a balance sheet reclassification of the value of these warrants from additional paid-in capital to a liability and a gain on derivative warrant liabilities. The company will value these warrants on a quarterly basis, which could result in additional gains or losses on derivative warrant liabilities. Please note that the reclassification and these gains or losses have no impact on cash, working capital, loss from operations, cash flows from operations, or Adjusted EBITDA. I will now build upon the comments Josh has already provided regarding our quarterly results, starting with revenue. Net revenue for the fiscal 2023 second quarter was $26.3 million compared to $23.1 million for the fiscal 2022 second quarter, a 14% increase. Looking at the component parts, net revenue from prescription product sales in the fiscal 2023 second quarter was $18 million compared to $14.6 million in the same quarter last year, an increase of 23%. As Josh noted, ADHD experienced 2% growth in net revenue to $11.1 million in the fiscal 2023 second quarter against $10.9 million during the fiscal 2022 second quarter. The prescription pediatric portfolio experienced 95% growth in net revenue to $6.3 million in our fiscal 2023 second quarter compared to $3.2 million in 2022. Again, this growth was somewhat muted due to the end of calendar year shipping delays that pushed revenue into the following quarter. For the second quarter of 2023, net revenue from the consumer health segment was $8.3 million compared to $8.5 million in the same quarter last year. A decrease of 3% attributed to the channel strategy shift Josh described. We continue to have a small amount of other prescription revenue both this year and last. This other pertains to discontinued or deprioritized prescription products. During this year's second quarter, it totaled $581,000 in net revenue. Last year's second quarter had $545,000 of net revenue. In general, we expect other revenue to decrease going forward. Gross margins improved strongly to 66% in the 2023 second quarter compared to 53% of net revenues in the year-ago like quarter. This improvement in gross margin percentage was primarily driven by product mix, improvements in the ADHD and pediatric product lines, a result of cost reduction efforts and greater volumes. Gross margin percentages can vary from period to period for various reasons. This improvement does not yet account for any improvements we expect from the manufacturing transfer we've discussed. We are optimistic that the margins will further improve upon the completion of the ADHD manufacturing transfer. On the OpEx side, for the second quarter of 2023, excluding impairment expense and amortization of intangible assets, operating expenses were $20.3 million compared to $22.1 million the same period a year ago. A decrease of about $1.8 million. Research and development expenses were $1.7 million in the second quarter of 2023 compared to $4.5 million in the 2022 second quarter. Of this $1.7 million, $1.3 million was expense associated with the recently suspended pipeline programs. This quarter's net loss was impacted by an intangible asset impairment charge of $2.6 million related to our now former drug candidate, NT-502, a result of our announced suspension of drug development. There were no impairments during the second quarter of fiscal 2022. The net loss for the second quarter of fiscal 2023 was $6.7 million or $2.15 per share, compared to $11.5 million or $8.74 per share for the same quarter last year. Adjusted EBITDA for the second quarter was a positive $727,000 compared to a negative $7.6 million a year ago. When you look at the breakdown by segment, Adjusted EBITDA for our prescription segment during the second quarter of fiscal 2023 was a positive $3.1 million compared to a negative $1.9 million in the year-ago quarter. In the consumer health segment, quarterly Adjusted EBITDA was a negative $1.1 million compared to a negative $1.5 million in the year-ago period, a 30% improvement year-over-year. Adjusted EBITDA tied to our now suspended R&D pipeline was a negative $1.3 million during the second quarter of fiscal 2023, compared to a negative $4.1 million in the second quarter of fiscal 2022. Going forward, we expect pipeline R&D spend to be minimal until such time that we can fund R&D from operations or engage a partner. Full reconciliations from net income to Adjusted EBITDA are provided in the tables included in today's press release. On the balance sheet, cash and cash equivalents at December 31, 2022, were $19.5 million compared to $23.8 million on September 30th, 2022. During the second quarter, we announced an agreement with Avenue Venture Opportunities Fund to extend the interest-only period of our existing senior secured loan facility to January of 2024. We discussed this extension in some detail during our previous quarterly conference call. Please refer to today's press release for a recap of the details. Let me note that we have implemented a 1 for 20 reverse stock split effective January 6th of 2023. This action enabled the company to regain full compliance with Nasdaq's listing requirements effective January 20th of this year. With that, let me turn it back over to Josh. Thank you, Mark. Let me just conclude with where I started. I'm extremely pleased with the recent momentum the business has gained as we re-report our second consecutive quarter of company-wide positive Adjusted EBITDA. The strategic decisions back in October of 2022 to accelerate the growth of our commercial businesses and indefinitely suspend our clinical development programs have put us on the path to profitability, evidenced by two consecutive quarters now of positive Adjusted EBITDA. With product tailwinds in both ADHD and our pediatric RX business, coupled with the shift within our consumer health business toward more profitable e-commerce sales and the upcoming launch of our Circle family of brands, I believe we are poised to continue the recent trends throughout the second half of the year. I appreciate everyone's participation on the call today and will now be happy to answer any questions you might have. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Jennifer Kim with Cantor Fitzgerald. Please proceed. Hi. Thanks for taking my questions and congrats on the quarter. I have a few questions here. The first one, I may have missed this, but the end of the year shipping delays on the ADHD portfolio, can you quantify how much was pushed into the third quarter? My second question is, could you give any more color on the impact to consumer health expected over the next few quarters in terms of the revenue impact relative to I guess the improvement in gross margins you'd expect? My last question is, manufacturing transfer, it seems like that's still on track. Do you still expect a 15% improvement in margins from that? Thanks. Hi, Jennifer. This is Mark. We have not quantified or disclosed what that push into the next quarter was. It's a, it's a material amount, but it's gross to nets obviously are, you know, are sort of unique in our industry as you know, Jennifer. Timing and things like that have a little bit of a lagging effect, so we've not quantified it at this point. Revenue impact on consumer health shift? Yeah, good question, Jennifer. You know, generally speaking, our mindset is exactly like you said, and like we said here. We're gonna focus much more on the bottom line for that segment than we are for the top line. It's not to suggest that sales are going to collapse in any, in any meaningful way. We think that they will be, you know, flat to down-ish, not massively, but, we do expect to see, you know, a nice improvement over the next handful of quarters in EBITDA with the hope that that business begins cash flowing. With respect to the tech transfer, it does remain on track. Yes, we do anticipate an incremental improvement on top of where we are today when we are finally, out of the Grand Prairie facility and into the new contract manufacturing facility. Any improvements would be in addition to what we've already gained just through some of the normal, some of the normal improvements that have happened here over the last year or so. Yeah. We're still targeting that 15 percentage points for the ADHD products, Jennifer. Great. Maybe if I could squeeze in one more question. R&D expense, do you still anticipate that to go down in the coming quarters, as you sort of move away from the costs associated with the pipeline program? Thanks. Yes. In the Or I'm sorry, this, the calendar, fiscal second quarter, excuse me, we had a few expenses related to wrapping up the AR101 trial. We'll have a few small ones going forward. There should be a significant decrease next quarter. All right. Thanks again. Thank you. Once again, if you have a question or a comment, please indicate so by pressing star one on your touch-tone phone. The next question comes from Vernon Bernardino with H.C. Wainwright. Please proceed. Hi, guys. Thanks for taking the question. Congrats on the great momentum. Just wanted to follow up on the previous questions. As far as the ADHD products are concerned, understand the taking advantage of the problems with the generics out there, but is there anything specific you could point to that help take up of, for example, Xanax XR ODT that you might be able to capitalize on that may further accelerate sales in that regard? You know, you said you couldn't quantify, but just wondering how much of those, or do you expect those sales that were deferred because of shipping issues in the calendar fourth quarter of 2022, might we see real soon or will it be down the road? Yeah. For the last question, Vernon, yeah, we should see it in the next quarter. Again, it's a couple of days of revenue and as you know, it's just a timing thing with the shipments. We recognize shipments based on when we deliver a product to the wholesalers. You know, A lot of it just depends on which day the orders and what have you. There were some delays because of the travel, both products that were in transit and, the timing of when they left our dock. That all got arrived in the next, the next week. In terms of your first question, Vernon, what gives us sort of comfort in the context of maybe continuing realization of these tailwinds? What I'll point out is it was interesting. When you looked at sort of the late summer, early part of the fall, the most immediate impact was actually with the immediate release, the Adderall, just regular Adderall IR. Then you would see sort of an impact sort of down the line. Of course, this channel is one whereby it starts obviously at the manufacturer, the manufacturer ships in the wholesaler, the wholesaler ships into retail, and then ultimately the patient picks up the prescriptions. That all takes a fair amount of time to work through, such that when the public is sort of being noticed of this shortage, there's a lagging effect in terms of when that ultimately affects the patient's ability to pick that up. There was a delay even further around the extended-release formulations of the Adderall generic, such that I would even say just now we're starting to get into the thick of that realization. Meaning really just now to the point that patients and physicians are starting to feel it on a consistent basis with the specifically with the extended release, such that we started to see, and I can share this because really prescriptions are all public, generally speaking. The impact that we're starting to see just started to rear its head really kind of in February. You can see the delayed nature of this effect whereby, you know, late fall, we had news releases. We even put out sort of, I know, communications and press releases indicating that our product, Adzenys, was still in good supply. It really took even through the holidays before we were comfortable that that was starting to be realized at the physician and patient level, such that for that week ending February tenth, prescriptions of Adzenys were up 26% sequentially. From that preceding week, they jumped up 26%, which is obviously a significant increase. No, no way to tell exactly how long we would expect this to continue, but I will say there's continuing to be a lot of discussion around that. We... You know, just last week, Bloomberg published yet another article, articles, far and wide around this continuing shortage and the issues and the pinch that it's really putting on patients. It's not gonna be something that lasts clearly forever, but it does seem like it is... we're still very much in the, you know, relative early to middle innings of this issue, such that we should be able to benefit from this for the foreseeable future. More to see there, but script trends are really encouraging when you look at the February scripts. Just to follow up on that, though. Would you consider this? I mean, it seems like demand is growing, and so it would not seem to be a zero-sum game. Do you anticipate perhaps that your Adzenys, taking advantage of those needs and shortfalls, for example, could be maintained? What efforts could you see that could accelerate that and then perhaps long term maintain that kind of, if you could characterize as, market share? Yeah, it's a good question. One thing that's important to note about ADHD, of course, is that it's chronic. Once you get a patient converted from a product like Adderall XR, you would expect to maintain that patient. So you're gonna see a step function and one that would sustain itself. You would not expect that a patient gets one prescription of Adzenys and then Adderall comes back in supply, and then they switch off of Adzenys and go back to Adderall. Quite the opposite, in fact. Once patients are on a product with which they're satisfied, they'll stay on it. So that annuity value is now coming off of an even higher base. If you look at new prescriptions, which generally speaking, all of these prescriptions in the stimulant class are considered new, but when you triangulate the data and look at new starts versus refills, you would clearly expect the refills to now be able to pivot off of a much higher baseline of new starts. That is what we're seeing, and that's one of the things that is exciting to us from a business perspective. Of course, from a humanistic perspective, we're able to, you know, wear the white hat, so to speak, and come in and be, you know, a real help to these patients and their families. Obviously from a revenue perspective, we are gonna operate off of, we think, a higher baseline from which to gain refills. It's exciting for us. We definitely are seeing signs that patients are starting on Adzenys or continuing on to Adzenys. Of course, we have the RxConnect platform that enables them to continue to have a good experience to get refills at a predictable copay, even at times of the year, like January, February, March, when they have a higher copay due to their deductible still needing to be worked down. We've got the ability to maintain these patients on such that as we get into the second half or even second sort of, two-thirds of the year, these patients' copays will maintain the same, and we'll obviously realize a higher net selling price by virtue of a lower buy down. The net benefit for this is tremendous for us as we think about the relative near term, and then as we go forward with higher refill rates and just more patients overall on therapy. Just to put a capstone on it, for us to hit 7,200 prescriptions in a week is by far the highest the brand has experienced in its history. That goes all the way back to when Neos had the brand and had almost 130 sales representatives selling it. We now have something in the neighborhood of 40 sales representatives selling it, and we've hit that all-time high. Things are clearly working, and it's a combination of these tailwinds that are brought about by the shortages, but it's really complemented by the sales force execution, this young, hungry sales force, coupled with the power and the leverage ability of Aytu RxConnect. All three of those things are working together right now to really drive prescriptions, and we're excited about where we are. Great. Thanks for taking my questions. I'm looking forward to those tailwinds being realized in the accelerated revenue. Thank you. Thanks, Vernon. We have reached the end of the question and answer session. I will now turn the call over to management for closing remarks. Thanks very much, John. Thanks to everyone for joining the call today. We appreciate everyone's participation. Looking forward to updating you on our next quarterly earnings call, which is scheduled for May. With that, thank you for your interest in Aytu. Thanks for attending, and everyone have a great afternoon or evening. Thanks very much. Take care. This concludes today's conference, and you may disconnect your phone lines at this time. Thank you for your participation.